Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q4 FY22 results · Jan–Mar 2022
Glenmark Pharmaceuticals reported revenue from operations of ₹3,019.15 crore (up 5.6% from Q4 FY21) and net profit of ₹172.57 crore (down 26.2% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,019.15 | 2,859.90 | +5.6% | 3,173.41 | −4.9% |
| Other income | 107.20 | 8.49 | 13x | 13.89 | +671.5% |
| Total income | 3,126.35 | 2,868.39 | +9.0% | 3,187.31 | −1.9% |
| Profit before tax | 269.69 | 337.51 | −20.1% | 343.04 | −21.4% |
| Net profit for the period | 172.57 | 233.87 | −26.2% | 239.75 | −28.0% |
| Attributable to shareholders of the company | 155.59 | — | — | — | — |
| EPS, basic (₹) | 5.51 | 8.29 | −33.5% | 7.86 | −29.9% |
| Net margin (%) | 5.7 | 8.2 | 7.6 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,785.54 | 1,850.37 | −3.5% | 2,033.05 | −12.2% |
| Other income | 178.98 | 116.86 | +53.2% | 216.74 | −17.4% |
| Total income | 1,964.53 | 1,967.23 | −0.1% | 2,249.80 | −12.7% |
| Profit before tax | 224.78 | 373.36 | −39.8% | 636.65 | −64.7% |
| Net profit for the period | 205.60 | 341.77 | −39.8% | 548.52 | −62.5% |
| EPS, basic (₹) | 7.29 | 12.11 | −39.8% | 19.44 | −62.5% |
| Net margin (%) | 11.5 | 18.5 | 27.0 |
Consolidated
- Filed with BSE
- 30 May 2022, 14:00 IST
- Board meeting
- 27 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 May 2022, 14:00 IST
- Board meeting
- 27 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE